HER3 

 79 Products   79 Products   118 Diseases   2688 News 


12345678910111213...2122»
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Gilotrif (afatinib) / Boehringer Ingelheim, Vizimpro (dacomitinib) / Pfizer
    Journal, Real-world evidence, IO biomarker, Real-world, Metastases:  Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors. (Pubmed Central) -  May 3, 2024   
    Median OS was 10.3 months (95% CI, 8.1-13.9) from pemetrexed-platinum initiation and 12.4 months (95% CI, 10.2-15.2) from platinum initiation; 12-month survival rates were 48% and 51%, respectively; 260 patients (84%) had died by the end of the study. The suboptimal survival outcomes recorded in this study demonstrate the unmet need to identify more effective subsequent treatment regimens for patients with EGFR-mutated advanced nonsquamous NSCLC after EGFR TKI resistance develops.
  • ||||||||||  patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), Tagrisso (osimertinib) / AstraZeneca
    HERTHENA Lung01 (Exhibit Hall) -  Apr 7, 2024 - Abstract #HOPA2024HOPA_404;    
    ERBB3 OE as a biomarker could thus stratify patients for intensification of therapy in castration-sensitive disease, including targeting HER3 directly to improve sensitivity to AR-targeted therapies. HERTHENA-Lung01 evaluated the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with EGFR-mutated NSCLC after progression with EGFR TKI therapy and platinum-based chemotherapy Learning Objectives:
  • ||||||||||  izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
    Trial completion date, Trial primary completion date, Metastases:  A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=26, Recruiting, 
    HERTHENA-Lung01 evaluated the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with EGFR-mutated NSCLC after progression with EGFR TKI therapy and platinum-based chemotherapy Learning Objectives: Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
  • ||||||||||  izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
    Trial completion date, Trial primary completion date, Metastases:  A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=96, Recruiting, 
    Trial completion date: Feb 2024 --> Aug 2024 | Trial primary completion date: Feb 2024 --> Aug 2024 Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
  • ||||||||||  izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
    Trial completion date, Trial primary completion date, Metastases:  A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor (clinicaltrials.gov) -  Apr 4, 2024   
    P1,  N=96, Recruiting, 
    Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024 Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim, Vizimpro (dacomitinib) / Pfizer
    Journal:  Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. (Pubmed Central) -  Apr 2, 2024   
    Two glioblastoma patients with somatic EGFR G598V dimerization domain mutations show responses to dacomitinib treatment followed by within-pathway resistance mutation in one case. In summary, this comprehensive screen expands the landscape of functional EGFR variants and suggests broader clinical investigation of EGFR inhibition for cancers harboring extracellular domain mutations.
  • ||||||||||  SIBP-03 / Sinopharm
    Journal:  SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs. (Pubmed Central) -  Mar 18, 2024   
    The mechanisms underlying this synergy involve increased inhibition of HER3-mediated downstream signaling. Collectively, these results demonstrated that SIBP-03, which is currently undergoing a Phase I clinical trial in China, may offer a new treatment option for patients with cancers harboring activated HER3, particularly as part of a combinational therapeutic strategy.
  • ||||||||||  patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
    Enrollment open, Pan tumor, Metastases:  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Mar 13, 2024   
    P2,  N=120, Recruiting, 
    Collectively, these results demonstrated that SIBP-03, which is currently undergoing a Phase I clinical trial in China, may offer a new treatment option for patients with cancers harboring activated HER3, particularly as part of a combinational therapeutic strategy. Not yet recruiting --> Recruiting
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, zenocutuzumab (MCLA-128) / Merus
    Role of tumor microenvironment derived NRG1 in androgen resistance: Implications for a novel prostate cancer treatment strategy (304A) -  Mar 12, 2024 - Abstract #AUA2024AUA_1240;    
    Activation of downstream PI3K-AKT signaling in a PCa epithelial cell line was seen after both recombinant NRG1 stimulation and culturing with cancer associated fibroblast conditioned media. This supports a paracrine mediated action of NRG1 whereby it is secreted by stromal cells in the tumor microenvironment to promote resistance through PI3K signaling.
  • ||||||||||  Pricing Strategies and Trends of FDA Approved NSCLC Therapies From 2018 to 2023 () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_333;    
    We extracted pricing data on 11 FDA approved novel NSCLC therapies (dacomitinib, capmatinib, entrectinib, selpercatinib, tepotinib, sotorasib, amivantamab, adagrasib, brigatinib, lorlatinib, pralsetinib), which are targeted therapies for specific mutations. In our analysis, NSCLC therapies launched at prices comparable to market competition with price increases comparable to inflation.
  • ||||||||||  DM002 / Doma Pharma, Biocytogen
    Preclinical Efficacy of DM002, a bispecific HER3 (Section 2) -  Mar 5, 2024 - Abstract #AACR2024AACR_5573;    
    DM002-BLD1102 also showed strong anti-tumor activity in DM002-vcMMAE resistant PDX models, suggesting the superiority of this new DNA topoisomerase I inhibitor linker/payload over the classical vcMMAE linker/payload. In conclusion, the HER3
  • ||||||||||  patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), R3Mab / Roche, seribantumab (MM-121) / Elevation Oncology
    Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers (Section 21) -  Mar 5, 2024 - Abstract #AACR2024AACR_5289;    
    Results from in vitro and in vivo studies highlight the promising therapeutic potential of a seribantumab-based ADC for patients with HER3-expressing cancers. Additional results on the optimization and characterization of HER3-ADC1 will be presented.
  • ||||||||||  Vizimpro (dacomitinib) / Pfizer
    Deep mutational scanning of EGFR reveals potential domain-specific TKI sensitivities in lung cancer and glioblastoma (Room 15 - Mezzanine Level - Convention Center) -  Mar 5, 2024 - Abstract #AACR2024AACR_3330;    
    Strikingly, at least two glioblastoma patients with G598V dimerization domain mutations showed responses to dacomitinib treatment together with subsequent off-target resistance in one case. In summary, this comprehensive screen reveals novel functional EGFR variants and suggests broader clinical investigation of EGFR inhibition for cancers harboring extracellular domain mutations.
  • ||||||||||  Tibsovo (ivosidenib) / Servier, seribantumab (MM-121) / Elevation Oncology
    Determining the molecular and biologic effects of HER3 and IDH1 antagonism on liver endothelium-PDAC crosstalk (Section 18) -  Mar 5, 2024 - Abstract #AACR2024AACR_2982;    
    Our results demonstrated a paracrine role of liver ECs in promoting cell growth via activating HER3 in PDAC cells as well as reprograming cellular metabolism from OXPHOS towards glycolysis. Identification of the metabolic shift that takes place in metastatic PDAC to the liver due to HER3 activation gives way for the development of a potentially lethal drug combination.
  • ||||||||||  izalontamab (SI-B001) / Biokin Pharma
    Trial completion date, Trial primary completion date, Metastases:  SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=40, Recruiting, 
    Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  izalontamab (SI-B001) / Biokin Pharma
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=60, Recruiting, 
    Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Vizimpro (dacomitinib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Phase 2 Study of Dacomitinib in NSCLC (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=118, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2023 --> Mar 2026
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Vizimpro (dacomitinib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (clinicaltrials.gov) -  Feb 15, 2024   
    P1,  N=22, Active, not recruiting, 
    Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2023 --> Mar 2026 Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025